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Correlation of clinical and in vitro erythropoietic responses to andro-
gens in renal failure. Ta assess in vitro erythropoietic cultures as a tool
to discriminate between patients whose anemia improves with and
those whose anemia fails to improve with androgens, bone marrows of
24 anemic patients receiving maintenance hemodialysis in hormone-
depleted plasma clots were cultured. While erythroid colony prolifera-
tion in the presence and absence of androgens by cells of seven patients
with good clinical outcomes who were initially studied was similar to
that of normal donors, it was reduced (P < 0.001) in cultures of cells
from seven patients whose clinical responses were ultimately poor.
Fewer than 25 colonies/6 x iO cells at optimal erythropoietin concen-
trations, and less than a 25% enhancement in colony growth by
androgens were observed in only those cultures derived from clinical
nonresponder marrows. Using these criteria, nine of ten prospectively
classified patients (five clinical responders and four nonresponders)
were identified correctly.
Correlation des réponses erythropoiétiques cliniques et in vitro aux
androgenes dans l'insuffisance rénale. Afin de determiner si les cultures
érythropoIétiques in vitro sont un outil permettant de discriminer entre
les patients dont l'anCmie s'améliore et ceux dont l'anémie ne s'amé-
liore pas avec les androgenes, nous avons cultivé des moelles osseuses
de 24 malades anémiques en hémodialyse pCriodique avec du plasma
déplété en hormone. Alors que Ia proliferation des colonies erythroIdes
en l'absence ou en presence d'androgenes a partir des cellules de sept
malades ayant une bonne evolution clinique étaient identiques a celle de
donneurs normaux, dIe était réduite (P < 0,001) dans les cultures
cellulaires provenant de sept malades dont les réponses cliniques se
sont révélées médiocres. Moms de 25 colonies/6 x l0 cellules a des
concentrations optimales d'erythropoIetines, et mains de 25% de stimu-
lation de Ia croissance des colonies par les androgenes étaient observes
uniquement dans les cultures provenant de moelle de non repondeurs
cliniques. En utilisant ces critères, neuf de dix malades prospective-
ment classes (cinq repondeurs cliniques et quatre non rCpondeurs) ant
été correctement identifies.
Today androgens are used widely to treat the anemia of end-
stage renal disease [1—41. Although an increased red cell mass
often results from therapy, transfusion requirement is unaltered
in many patients [5—7]. When successful, their action may be
attributed to either a direct effect on erythropoietic stem cell
proliferation or an indirect effect via enhanced erythropoietin
production 18—111. We recently observed variable erythroid
colony growth by cultured bone marrow cells from three uremic
patients whose anemia improved with androgen treatment [12].
These observations prompted us to measure erythroid colony
growth prior to androgen therapy in 24 patients receiving
maintenance hemodialysis with stable, chronic renal insuffi-
383
ciency. We now report that the numbers of erythroid colonies
formed in culture and the in vitro sensitivity of erythroid
progenitors to androgens correlate with clinical responsiveness
to androgen therapy. In vitro clonal assays may be of potential
use in discriminating between patients with chronic renal failure
who will and those who will not respond favorably to such
therapy.
Methods
Patient population. We initially studied 14 males and 6
females with chronic renal failure and anemia who received
maintenance hemodialysis for 7 to 97 months. Informed consent
was obtained prior to their receiving androgen therapy. Their
mean age was 49 years. Ten patients had glomerulonephritis,
three polycystic kidney disease, five nephrosclerosis, one ne-
phrotic syndrome and one retroperitoneal fibrosis. The mean
value for their blood urea nitrogen was 77 mg/dl (with a range of
51 to 96 mg!dl); for their serum creatinine, 10.9 mg/dl (range of
6.5 to 17.4 mg/dl); for their serum calcium, 9.4 mg/dl (range of
8.6 to 11.4 mgldl); for their serum phosphorous, 4.1 mg/dl
(range of 2.4 to 7.7 mg/dl); and for their alkaline phosphatase, 80
U/ml (range of 28 to 339 U/ml). C-terminal PTH assays showed
a mean serum parathyroid hormone level of 396 ng/ml (range of
191 to 548 ng/ml). Nineteen patients were clinically stable on
dialysis for 4 hr, three times a week with a hollow fiber or coil
dialyzer. One patient was treated with a plate dialyzer for 6 hr,
three times a week at home. None of the patients underwent
parathyroidectomy prior to or during the study.
Table 1 displays a clinical summary of the initial 20 patients
studied. Two patients with glomerulonephritis were anephric
(Table 1). Three patients experienced kidney transplant rejec-
tions from 4 months to 2 years prior to the study (two were from
cadavers and one was from a related living donor; Table 1).
The mean SEM value in all 20 patients for hemoglobin was
6.9 0.3 g/dl; for their reticulocyte index, 0.3 0.38%; for
their absolute neutrophil count, 4,463 120/mm3; for their
absolute lymphocyte count 1,330 52/mm3, and for their
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Table 1. Clinical data and response to therapy for the initial 20 patients studied
15 8.7 10.9 0.4
IS 9.5 12.8
27 9.0 11.5
9 9.1 12.3
27 6.9 8.3
29 5.8 7.9
25 6.1 7.2
3.8 2.1 Andro
Nandrolone
1.9 0.1 Nandrolone
2.0 0.3 Nandrolone
2.4 0.5 Nandrolone
4.6 3.0 Nandrolone
6.0 3.8 Nandrolone
5.2 3.6 Nandrolone
platelet count, 209,500 1503/mm3. While the seven clinical
responders had slightly higher hemoglobin values (mean SEM
of 7.9 0.5) than those of the seven nonresponders (6.3 0.4)
at the onset of the study, these levels were insignificantly
different (P > 0.10) (Tables 1 and 2). There was no significant
difference between the pre-treatment transfusion requirements
for clinical responders (mean SEM of 3.7 0.8 PRC per
patient per month) and clinical nonresponders (4.2 0.7).
Splenomegaly was present in two patients at the time of the
study (Table I). Even though red cell sequestration studies
were not performed, a significant hemolytic component to
anemia was unlikely in these patients, as assessed by reticulo-
cyte count, LDH, and indirect bilirubin levels. There was no
apparent difference in blood loss at dialysis among the patients.
Bone marrow aspiration and biopsy specimens were obtained in
14 patients; cellularity assessed on biopsy specimens was
normal in two patients, increased in two patients and decreased
in the remaining ten patients. The myeloid to erythroid ratio
varied from 2:1 to 4:1. Marrow iron stores were absent in two
patients, reduced in four patients, and normal or increased in
eight patients. Megaloblastic changes were not observed.
Therapy of anemia in all 20 patients included folic acid and a
diet consisting of greater than 1 g of protein/kilogram. Oral
ferrous sulfate was administered to the six patients (three
clinical responders and three nonresponders to androgens)
whose marrow iron stores were less than normal. A higher
incidence of iron deficiency was not observed in our patients,
owing possibly to our liberal transfusion policy. Therefore,
nutritional deficiencies were either ruled out as a factor or
corrected. No patient received oral anticoagulants, and none
had gastrointestinal bleeding as assessed by repeated stool
guaiac testing during the study period. Other therapies of
anemia included the administration of androgens and blood
products.
Androgen therapy. Androgens administered to the initial ten
males and four females (Table 1) were selected according to the
preferences of the referring nephrologist. Six patients refused
androgen treatment and marrow aspiration; they received dialy-
sis without androgens and were considered untreated controls.
Eight patients received nandrolone decanoate alone, 2.5 to 3.0
mg/kg i.m. weekly; one patient, fluoxymesterone, 0.4 mg/kg/
day; three patients, androsterone alone, 1 mg/kg/day; and one
Transfusions,
Dialysis Hgb, gidi no. PRC/Moc
Patient Sex Duration Reticulocyte Androgen
no. Dxa age in yr Typeb mo Pre Post index, % Pre Post therapyd
PKD F (50) CResponders
2 UN
3 GN
4 NS
5 GN
6'
7 NS
Non-responders
8
9 GN
10 NS
11 GN
12 RF
13 GN
14 PKD
M (57)
M (74)
M (66)
M (42)
M (26)
F (40)
M (48)
M (29)
F (78)
M (67)
M (65)
M (36)
F (20)
F (68)
M (50)
M (39)
M (54)
F (75)
M (65)
HF
HF
HF
C
HF
HF
HF
HF, C
HF, C
HF
HF
HF, C
HF
HF
HF, C
PP
C
HF
HF
Untreated
15
16
17
18
19
20
0.3
0.6
0.5
0.1
0.2
0.3
0.1
0.1
0.1
0.1
0.3
0.4
0.2
0.3
0.5
0.3
0.2
0.6
0.5
UN
NS
PKD
NS
UN
GN
7 6.5 4.8
15 6.0 6.3
27 6.5 6.5
31 4.9 5.4
39 6.3 6.2
27 7.6 7.4
28 6.5 6.8
28 5.8 5.9
14 7.5 7.4
10 6.5 6.4
15 4.7 5.0
9 8.3 8.0
II 7.0 6.9
5.0 5.5 Fluoxy
5.0 4.8 Testos En
4.2 4.2 Nandrolone
6.0 5.9 Andro
3.9 4.4 Andro
2.0 3.0 Andro
3.0 3.0 Nandrolone
5.0 5.7 None
2.0 1.9 None
4.9 4.0 None
5.9 6.0 None
2.0 1.9 None
3.0 3.0 None
a Abbreviations of diagnoses are: PKD, polycystic kidney disease; GN, glomerulonephritis; N, nephrotic syndrome; NS, nephrosclerosis; RF,
retroperitoneal fibrosis.
Dialysis types are: PP, parallel plates; HF, hollow fiber; C, coil.
Number of transfusions per patient per month required to maintain a hemoglobin value of >7 g/dl and relieve symptoms attributable to anemia,
during the 1 month prior to (Pre) and the 6th month after (Post) the initiation of androgens. Untreated patients received dialysis without androgens.
Patients received 2 U of PRC with each transfusion.
d Abbreviations of androgen therapy are: Andro, androsterone; Nandrolone, nandrolone decanoate; Fluoxy, fluoxymesterone; Testos En,
testosterone enanthate.
a Anephric at study time.
Splenomegaly at study time.
Patients 8 and 9 received cadaver kidneys and patient 6 received a live donor kidney.
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Table 2. Correlation of clinical and in vitro responses to nandrolone decanoate in ten prospectively classified patients with glomerulonephritis
Transfusions,
Patient Sex
Erythroid cultures"
Dialysis
duration°
Hgb, gIdl no. PRC/mo"
No. CFU-E/ Percent
no. age in yr 6 x io cells stimulation mo Pre Post Pre Post
Responders
21 M (52) 31 5 97 31 7.5 10.3 4.4 2.1
22 F (49) 20 3 112 62 6.9 8.9 2.4 0.9
23 F (61) 58 12 68 57 8.4 11.2 2.8 1.0
24 M (26) 80 16 22 17 7.6 12.4 3.5 1.1
25 F (43) 36 7 90 28 8.0 10.1 2.2 0.6
Mean SEM 45 12 78 10 39 10 7.6 0.6 10.6 0.3 3.1 0.5 1.1 0.4
Non-responders
26 M (20) 14 3 12 52 6.7 9.0 3.6 1.5
27 F (66) 5 2 0 22 7.8 6.7 4.6 4.2
28 F (41) 20 1 15 7 6.1 6.5 3.1 4.0
29 F (26) 22 5 19 43 6.6 7.1 2.0 2.3
30 M (30) 4 1 0 97 7.3 7.0 3.7 3.0
Mean SEM 13 5 9 4 44 17 6.9 0.3 7.3 0.5 3.4 0.5 3.0 0.6
a Mean SEM number of CFU-E-derived colonies formed at 2.0 lU/mi erythropoietin and the mean percentage increase in colonies relative to
controls containing NCTC-109 by the addition of l07M androsterone, etiocholanolone, or fluoxymesterone are shown.
b All patients were clinically stable on dialysis for 4 hr, three times weekly with a hollow fiber dialyzer.
See footnote to Table 1.
patient, testosterone enanthate, 4 mg/kg i.m. weekly (Table 1).
One patient received androsterone, I mg/kg/day for 9 weeks,
followed by nandrolone decanoate, 2.5 mg/kg i.m. weekly for
the remainder of the study period (patient no. 1, Table 1).
Because we observed an apparently higher favorable response
rate with nandrolone decanoate in these 14 patients (Table 1),
the remaining ten patients who were studied prospectively were
treated with this androgen, 2.5 to 3.0 mg/kg i.m. weekly. Once
androgens were initiated, none of the 24 patients refused
therapy during the study period.
Transfusion therapy. All patients were administered 2U of
washed frozen red cells (PRC) when their hemoglobin levels
declined to 7.0 g/dl or less. In addition, in some patients
transfusions were given at hemoglobin levels of between 7.0
and 8.0 g/dl for development of the following specific symp-
toms: claudication, angina, recurrent palpitations and vertigo,
and severe exercise intolerance.
Clinical response to therapy. In vivo response to therapy was
determined by assessing the average number of units transfused
and the average hemoglobin level during the one month prior to
study (initial values) and during the sixth month after initiation
of androgen therapy (final values). Responders were defined as
those in whom there was a greater than 30% decrement in
transfusion requirements from initial to final values associated
with a greater than I g/dl increment in average hemoglobin
level. Nonresponders were defined as those in whom transfu-
sion requirements were unaltered, increased or diminished by
less than 30% and in whom a less than 1 g/dl increment in
average hemoglobin level was observed after 6 months of
therapy.
In vitro androgen stimulation tests. Bone marrow cells from
the posterior iliac crests of ten hematologically normal volun-
teers and the 24 patients who received androgen therapy were
aspirated into Eagle's minimum essential medium after in-
formed consent was obtained. In two patients a second aspirate
was obtained for patient marrow culture. The nucleated cells
were separated over Ficoll-Hypaque, washed three times in
Eagle's minimum essential medium and cultured at 6 x l0 cells
per milliliter in hormone-depleted plasma clots in the presence
of 0.0, 0.5, 1.0, 2.0, and 4.0 IU per milliliter (IU/ml) of
erythropoietin (Sheep Step III, Connaught Labs, Canada),
according to Tepperman, Curtis, and McCulloch 1131. Fetal calf
serum, bovine plasma, and bovine serum albumin were mixed
for 12 hr at 40 C with radioimmunoassay grade charcoal to
deplete these culture constituents of hormones known to be
active in vitro [141. Levels of testosterone, estradiol, cortisol,
insulin, thyroxine, and triiodothyronine were undetectable after
charcoal adsorption.
Three classes of androgens were tested in culture. The
synthetic -4 androstene fluoxymesterone (fluoxy 11, 17 13-
dihydroxy-a fluoro- I 7cs methyl-H-androstan-3-one), the natu-
rally occurring, non-androgenic 5f3-androstane etiocholanalone
(etio-3-hydroxy-5-androstane- 17-one) and the 5a-androstane
androsterone (3a-hydroxy 5a-androstane-17-one) were dis-
solved in 95% ethanol, diluted in NCTC-l09 containing penicil-
lin and streptomycin, and added to culture at the final concen-
tration of i07 M. Cultures were maintained in a humidified
atmosphere of 3% carbon dioxide in air at 37° C. After 7 days of
incubation, the clots were removed from incubation, fixed in
glutaraldehyde to glass slides, and stained with benzidine and
hematoxylin to determine the number of hemoglobinized colo-
nies that had formed. Each clot was examined under xlOO
magnification, and erythroid colonies consisting of 8 to 49
benzidine-positive cells were scored as colony forming units-
erythroid (CFU-E derived colonies).
Erythropoietin measurements. At the onset of therapy, sera
from 12 patients with renal insufficiency (six who were classi-
fied ultimately as responders, five as non-responders and one as
an untreated patient) were entered initially into the study. Sera
from five patients with aplastic anemia (mean SEM value for
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p<0.001 p<0.001 p<0.001 • P<0.001
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Erythropoietin concentration, lU/mi
Fig. 1. Erythroid colony formation at various ervthropoietin doses.
Marrow cells were cultured at 6 x IO cells/mi from ten hematologically
normal donors (circles), seven patients with a favorable clinical re-
sponse to androgens (triangles), and seven patients whose clinical
response was poor (squares). Bars indicate the geometric means for the
values in each group. Comparison of the means and analysis of variance
demonstrates significant differences between growth observed in cul-
tures from normal donors and growth in cultures from unresponsive
patients at each erythropoietin dose tested. Outcomes obtained with
marrow cells from responsive patients are similar at each erythropoietin
concentration to those obtained with cells from normal donors. NS is
not significant.
their hemoglobin of 7.3 1.5 g/dl) were collected sterilely and
immediately frozen at _400 C until assays were done. Four
days after polycythemia was induced by hypertransfusion of
CF1 female mice (Carworth Labs, Woburn, Massachusetts),
1.00 ml of test serum (0.50 ml on 2 consecutive days) were
injected subcutaneously into five animals. Mice with hemato-
crits of less than 55% were excluded from assay. 59Fe was
injected into the tail veins 24 hr later, and its incorporation into
circulating red cells was determined after 24 hr, according to the
methods of Shadduck, Howard, and Stohiman [15]. Normal
saline and sheep step III erythropoietin (Connaught Labs,
Canada) were tested concurrently, and activities of test samples
were calculated. Sera from nonanemic healthy adults regularly
contain less than 0.025 U/mi activity in our laboratory. Six
months after the initiation of androgens, serum from all six of
these androgen-responsive patients and from one of the unre-
sponsive patients was collected, and erythropoietin measure-
ments were made.
Serum testosterone measuretnents. Testosterone levels were
determined by radioimmunoassay (normal range of 300 to 1,200
ng/dl in adult males) in sera obtained just prior to and 3 months
after the onset of therapy in the 14 males (eight clinical
responders and six nonresponders) who received androgens.
Statistical methods. For bone marrow cultures, the mean
SEM of quadruplicates was determined. Data sets were com-
pared by the two-sample ranks test of Wilcoxon-White [16]. For
comparisons of groups, the geometric means were calculated
and the outcomes were compared by analysis of variance
followed by the Newman-Keuls multiple comparison test [171.
Correlation coefficients (r) were determined with standard
statistical techniques [171.
Results
Clinical response to therapy. Seven of the 14 patients initially
studied had a good clinical response to treatment with nandro-
lone decanoate (all seven patients) and androsterone (one
patient, Table 1). The mean transfusion requirement significant-
ly declined (P < 0.05) from an initial mean value of 3.7 to a final
value of 1.9 PRC transfused per patient per month. The mean
SEM hemoglobin increased from 7.9 0.5 g/dl to 10.0 0.6 g/dl
(P <0.05) during this time. Clinical response to androgens did
not correlate with duration of dialysis, level of azotemia, cause
of renal failure, prior renal transplantation or prior nephrecto-
my (Table 1).
In contrast, the transfusion requirements after therapy in the
remaining seven patients were unchanged: initial mean value of
4.1 and final value of 4.4 PRC transfused per patient per month.
The mean SEM hemoglobin during this time was also un-
changed: from 6.3 0.4 g/dl to 6.2 0.6 g/dl. Moreover, there
was no significant difference in mean transfusion requirement
(from an initial value of 3.8 to a final value of 3.7 PRC
transfused per patient per month) or mean SEM hemoglobin
level (from 6.6 1,2 to 6.6 1.0 g/dl) in the six control subjects
who were treated with dialysis alone (Table 1).
Side effects associated with androgen administration included
the elevation of transaminase levels in one patient, requiring the
substitution of nandrolone decanoate for androsterone (patient
no. 1, Table 1) 9 weeks after initiation of treatment. Hirsuitism,
deepening of the voice, acne and flushing of the skin were
observed in the majority of treated patients.
Androgen stimulation in vitro in initial bone marrow cultures.
Mean erythroid colony growth in cultures of normal donor cells
and of cells from the seven patients with favorable clinical
outcomes was similar at each erythropoietin concentration
tested (Fig. 1). However, it was significantly reduced relative to
normal at each erythropoietin dose (0.5, 1.0, 2.0, and 4.0 IU/ml)
in cultures of cells from the seven clinically unresponsive
patients (F = 26, 43, 17, 9, respectively; P < 0.001 for each).
While there was an insignificant difference between observa-
tions in cultures of normal donor and clinical responder marrow
cells, colony formation was reduced significantly in cultures of
clinical nonresponder marrow cells relative to that in cultures of
normal donor or clinical responder cells (P < 0.01 for both).
Figure 2 demonstrates that colony stimulation by androgens
of the three classes tested in vitro was similar in culture of
normal donor cells (geometric mean of 80% and two thirds of
the values between 47 and 135%) and of clinical responder
patient cells (geometric mean of 70% and two thirds of the
values between 25 and 194%). In contrast, it was diminished
significantly (F = 28; P < 0.001) in cultures of cells from
clinically unresponsive patients (geometric mean of 10% and
two thirds of the values between 2 and 45%). This was also true
for in vitro tests with androgens of the same class used in vivo
(F = 20; P < 0.001). The differences between stimulations of
colony growth by all three androgens tested and by androgens
of the same class used in vivo were not significant. However,
stimulation was reduced significantly in cultures of nonre-
sponder patient cells, relative to that in cultures of normal
donor and responsive patient cells (P < 0.01 for both).
At the optimal erythropoietin dose of 2.0 lU/mi, fewer than
25 colonies/6 x l0 cells formed in cultures of marrow from all
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Fig. 2. Stimulation of colony formation by androgens. The percent
increase in CFU-E-derived colonies per 6 x marrow cells by the
addition of 107M androsterone (A), etiocholanolone (U) or fluoxymes-
terone (I) to cultures with 2.0 lU/mi erythropoietin are computed
relative to controls in respective studies containing 2.0 lU/mi erythro-
poietin and NCTC-109. Tests with androgens of the same class used in
vivo are recorded for cultures of patient marrow cells. Bars indicate the
geometric means and their standard deviations for the values in each
group. Comparison of the means and analysis of variance demonstrates
a significant difference between stimulation in marrow cultures of
clinically unresponsive patients and of normal donors, whereas stimula-
tion in marrow cultures derived from clinically responsive patients and
from normal donors is similar. NS is not significant.
seven nonresponders, whereas greater than 25 colonies/6 X i04
marrow cells formed in cultures of five of seven responders and
of all ten normal donors (Fig. 1). In addition, there was less than
25% augmentation in colony growth by androgens of at least
one class in cultures derived from all seven clinical nonre-
sponders. This was true in cultures from only one of seven
responders and one of ten normal donors (Fig. 2).
Although observations with responders and nonresponders
overlapped considerably when each of these tests (colony
formation in the presence of erythropoietin alone and percent
stimulation by androgens) was evaluated by itself, the two in
vitro tests evaluated concurrently correctly identified all of the
responders and nonresponders (Fig. 3). When the number of
colonies formed at the erythropoietin dose of 2.0 IU/ml was
greater than 25/6 x i04 cells and stimulation by steroidal agents
was greater than 25%, the clinical response to androgens was
invariably good. Using both of these cutoff points as in vitro
criteria of response, all of the nonresponders and five of seven
responders who were studied initially could he identified.
Second marrow cultures were established with cells from
patients identified as numbers 3 and 5 (Table 1) at 14 and II
months, respectively, from the onset of therapy. Androgens
50 75 100
Number of CFU-E-derived colonies
Fig. 3. In vitro criteria of response. Each clinical responder (triangles),
clinical non-responder (squares), and hematologically normal donor
(circles) is identified as a single observation. Mean percent stimulation
of colony growth by l07M androsterone, etiocholanolone, or fluoxy-
mesterone is displayed relative to the number of colonies formed by 6 x
l0 cells in the presence of 2.0 lU/mi erythropoietin and NCTC-109.
Dashed lines indicate criteria of response selected after clinical out-
comes in the initial 14 patients studied (closed symbols) were deter-
mined. Note that for these 14 patients the appearance of less than 25
colonies together with less than 25% augmentation of colony formation
occurred only in cultures derived from non-responder marrow cells.
Open symbols denote observations in marrow cultures of ten prospec-
tively classified patients (see Results).
were discontinued when clinical responses were judged to be
poor; this occurred at 8 and 5 months, respectively, prior to the
second study. At 2.0 lU/mI of erythropoietin, fewer than 25
colonies/6 x io marrow cells formed and less than 25% colony
stimulation occurred in the second marrow cultures, similar to
findings in the initial studies.
In general, within each study statistically significant (P <
0.01) colony enhancement by androgens of one class was
associated with similar degrees of stimulation by androgens of
other classes. In studies of each source of marrow cells, no
single agent was significantly more or less stimulatory than the
others as determined by analysis of variance. In all patients,
colony formation by cells from clinical responders or nonre-
sponders were stimulated or unaffected, respectively, by andro-
gens of the same class used in vivo. Severity of azotemia or
duration of dialysis did not correlate with numbers of erythroid
colonies formed or with in vitro sensitivity to androgens.
Clinical and in vitro responses in prospectively classified
patients. With these preliminary findings, we prospectively
classified ten patients with glomerulonephritis into responder
and nonresponder groups based upon erythroid colony forma-
tion in cultures of their bone marrow cells. A clinical summary
of these patients is given in Table 2. All were stable on dialysis
for glomerulonephritis and none received kidney transplanta-
tions. Each patient received nandrolone decanoate without
physician knowledge of the culture results.
In five patients, greater than 25 erythroid colonies/6 x lO
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Transfusions/pt/mo
Fig. 4. Relation between percent increase in erythroid colonies and
change in transfusion requirement in the 14 patients initially studied
(closed circles) and the ten patients who were prospectively class(fied
(open circles). Mean percent stimulation of CFU-E formation with
107M androsterone, etiocholanolone, or fluoxymesterone in cultures
of 6 >< l0 marrow cells containing 2.0 lU/mi erythropoietin was
calculated relative to controls containing NCTC-l09. The change in
number of PRC transfused per patient per month was determined by
comparing average initial and final values. There is a significant
correlation between percent stimulation and absolute change in transfu-
sion requirement for all 24 patients studied (r 0.66; P < 0.001). The
line drawn represents the least square fit.
cells appeared in culture and/or a mean of 25% or more
increment in colonies was observed in cultures containing
androgens; patients with these in vitro findings were classified
as responders (Table 2). In five patients, these criteria were not
met; these patients were classified as nonresponders. Six of the
ten patients had a favorable clinical response to androgens,
including all five patients categorized as responders and one
additional patient categorized as a nonresponder (patient no.
26, Table 2). The remaining four patients, all classified as
nonresponders, had a poor clinical response to therapy. Thus,
nine of these ten patients were identified correctly by the in
vitro test (Fig. 3).
For the entire series of 24 treated patients, the change in
transfusion requirement for initial to final values correlated
significantly with the degree of in vitro stimulation of erythroid
colony growth by androgens (r = 0.66; P <0.001) (Fig. 4). This
was also true for the initial 14 patients studied (r = 0.73; P <
0.01) and for the ten prospectively classified cases (r = 0.57; P
<0.05). A similar correlation was observed between change in
average hemoglobin level and colony stimulation (data not
shown).
In the entire group of 13 responders (Tables 1 and 2), the
mean SEM serum testosterone level increased from 205 20
to 395 42 ng/dl (P < 0.05), while in nonresponders it rose from
154 35 to 493 110 ng/ml (P < 0.05).
Erythropoietin activity. There was no difference between
59Fe incorporation evoked by normal saline and that by each of
the 13 patient sera (Table 3). In contrast, sera from the five
patients with aplastic anemia contained between 88 and 650
mU/mi activity. Furthermore, serum collected 6 months after
the initiation of androgens from each of the six clinically
responsive patients and from one of the clinically unresponsive
patients, also contained undetectable levels of erythropoietin
(Table 3).
Discussion
The risks and high costs of transfusion therapy make andro-
gens a preferable form of therapy in anemic patients receiving
maintenance dialysis 11—41. We observed few complications
from this therapy. However, it is well known that patient
intolerance to androgens is high, making their routine use less
desirable [5, 181. Therefore, a reliable screening test for the
selection of patients for androgen therapy would be of great
value. Bagby, Gabourel, and Linman have indicated that in
vitro myeloid culture techniques may be helpful in selecting
patients with preleukemia syndromes for glucocorticoid thera-
py [19]. In vitro studies of erythroid progenitor sensitivity to
growth hormone have been used to study the biologic defects in
Laron dwarfism and may prove useful in predicting clinical
responses to this hormone [201. The present studies suggest that
erythroid clonal assays are of value in identifying patients with
endstage renal disease who are likely to benefit from androgen
therapy.
Androgens with an angular configuration (5J3) enhance the
effects of erythropoietin on normal hematopoietic cells [21].
Steroid effects include stimulation of marrow heme synthesis
[22—241 and augmentation of growth by pluripotential [251 and
differentiated stem cells [9—Ill. Erythroid progenitor cells from
patients with hypoproliferative anemias variously retain andro-
gen sensitivity [121. Here, we observed that in hormone-
depleted marrow cultures significant reductions from normal in
baseline colony growth (<25 colonies/6 x l0 cells at optimal
erythropoietin doses) and in the colony enhancing effects of
androgens (<25% stimulation) augur a poor clinical response to
androgen therapy. By applying these criteria in a prospective
classification of ten patients, the in vitro assay correctly identi-
fied five of the six subjects who were ultimately clinically
responsive to androgens and all four clinical nonresponders
(Fig. 3 and Table 2). Not only change in the number of PRC
transfused per patient per month but also change in the average
hemoglobin level correlated significantly (P < 0.001) with in
vitro response of patient cells to androgens.
The clinical responders and nonresponders had similar sever-
ities of anemia, blood transfusion requirements prior to thera-
py, amounts of blood loss, and nutritional requirements. More-
over, in vivo response could not be attributed to attaining
different circulating steroid levels, although sex-binding globu-
lins were not measured and drug concentrations in other
hematopoietic tissues may have varied [261. In addition, serum
erythropoietin activities were reduced similarly in androgen
responsive and unresponsive patients, and they remained low
after a favorable clinical outcome was achieved. The latter
finding suggests that in vivo effects of androgens were not
mediated by enhanced renal and/or extrarenal production of
erythropoietin. In contrast, androgens may have had a direct
stimulatory effect on target cells in the marrow. Our marrow
culture results suggest that the presence of adequate numbers of
normally proliferating erythroid progenitors which also retain
normal sensitivity to androgens is required for and may explain
a favorable clinical response to androgen therapy.
Erythropoietin responsiveness of bone marrow from uremic
animals and patients with renal insufficiency is often diminished
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Table 3. 59Fe incorporation
Material tested
Mean % 1 SEM
incorporationa
Activityb
inU/mi
Standards
Normal saline 0.01 0.01 —
Erythropoietin, 0.25 lU/mi 2.84 0.19 —
Erythropoietin, 0.50 lU/mi 7.74 0.64 —
Erythropoietin, 1.00 lU/mi 9.98 1.05 —
Patient serum concentrations
No. Dx Sample
0.00 0.00
0.00 0.00 (P > 0.10)
Un
Un
4 NS Pre-treatment
Post-treatment
2 GN Pre-treatment
Post-treatment
0.00 0.00
0.00 0.00 (P > 0.10)
Un
Un
3 GN Pre-treatment
Post-treatment
0.00 0.00
0.00 0.00 (P > 0.10)
Un
Un
5 GN Pre-treatment
Post-treatment
0.00 0.00
0.00 0.00 (P > 0.10)
Un
Un
6 GN Pre-treatment
Post-treatment
0.01 0.01
0.01 0.01 (P > 0.10)
Un
Un
8 N Pre-treatment
Post-treatment
0.00 0.00
0.00 0.00 (P > 0.10)
Un
Un
7 NS Pre-treatment
Post-treatment
0.01 0.01
0.00 0.01 (P > 0.10)
Un
Un
12 RF Pre-treatment 0.02 0.01 Un
10 NS Pre-treatment 0.00 0.00 Un
18 NS Pre-treatment 0.00 0.00 Un
9 GN Pre-treatment 0.00 0.00 Un
11 GN Pre-treatment 0.00 0.00 Un
Aplastic anemia serum concentrations:
AA — 10.09 0.94 350
2 AA — 6.06 0.55 175
3 AA — 12.74 0.73 650
4 AA — 2.99 0.25 88
5 AA — 5.02 0.70 136
a Mean percentage of 59Fe incorporation in five animals per 0.5 ml of either test serum or standard material. P values are computed relative to ob-
servations in respective pre-treatment samples.
b Activity: milliunits per milliliter; Un, undetectable. Patient serum concentrations are designated according to numbers assigned in Table I.
[27—29]. Our findings agree with a recent report that in uremia
the sensitivity of erythroid progenitors to erythropoietin does
not correlate with the degree of azotemia [29]. They also
indicate that both normal and reduced in vitro marrow cell
sensitivity to erythropoietin as well as to androgens may be
found in this population. It is not known why these two distinct
responses are present. We may speculate that in some cases
bone marrow-derived erythroid progenitor cells or other mar-
row cells that interact with progenitors have quantitative reduc-
tions in available growth factor receptors or functionally abnor-
mal hormone receptors. Furthermore, molecules having an
inhibitory action on erythroid cell division may bind and/or
sterically alter critical cell surface components. For example,
humoral suppression of erythroid cell proliferation and heme
synthesis may occur in renal insufficiency [30, 311. Recently, a
dialyzable, low molecular weight inhibitor of proliferation by
erythroid progenitors, spermine, has been identified in serum
from uremic subjects [321. Others have suggested that parathy-
roid hormone and/or C-terminal fragments of this hormone may
suppress erythropoiesis [33, 34]. Variations in levels of such
uremic inhibitors may explain impaired erythropoietic respons-
es to androgens in some patients with renal failure, while in
other patients the responses are normal.
Although hemodialysis may improve anemia, erythropoietin
production is unchanged, suggesting that elimination of such
inhibitors may be clinically significant [35]. Anemia was unal-
tered in our six patients treated with dialysis alone. Since these
patients received dialysis for a mean of 15 months prior to the
study (Table 1) and because dialysis frequency was the same
prior to and during the study period, improvement in anemia
due to accelerated removal of such inhibitors was not
anticipated.
Patients with bilateral nephrectomies often fail to respond to
the usual doses of androgens [3, 36]. This observation has been
attributed to the requirement for a critical mass of erythropoie-
tin-producing renal tissue. Others have observed that nephrec-
tomized patients respond equally well to these agents [37, 381.
Two of our clinical responders were anephric at the time of
study (patients 6 and 9, Table 1). As with the other treated
patients, their pre- and post-treatment sera contained undetect-
able erythropoietin activities. One explanation for this observa-
tion is that androgens stimulate the growth of erythroid progeni-
tors by enhancing their sensitivity to trace amounts of erythro-
poietin derived from either renal or extrarenal sources.
Although the in vivo bioassay in polycythemic mice used
here is currently one of the most widely used and reliable tests
390 Kalmanti et a!
to measure erythropoietin activity [391, it lacks the precision to
detect titers in the normal range. Recently, its sensitivity has
been improved by plasma concentration [401, Utilizing this
technique, Caro et al have demonstrated two patterns of
erythropoietin activity in patients with renal insufficiency; that
is, those whose erythropoietin levels are normal and those
whose levels are diminished following concentration [33]. Fur-
ther studies with this and other assays [41, 42] may shed light on
the mechanisms by which androgens stimulate red cell produc-
tion in anephric individuals.
In conclusion, our observations suggest that anemic patients
receiving maintenance hemodialysis are likely to respond to
androgens, if in vitro cultures of their marrow cells demonstrate
normal proliferations of erythroid progenitors in the presence
and absence of androgens. It appears that studies designed to
evaluate the predictive value of this in vitro test in a larger
patient population should be performed.
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